A woman gets a yeast infection when the vaginal environment shifts in a way that lets Candida, usually Candida albicans, shift from a harmless colonizer to an overgrowing opportunist. The trigger is rarely a single event. It is a change in estrogen, pH, glycogen availability, local immunity, or the bacterial community that normally keeps yeast in check. Antibiotics, high-estrogen states, uncontrolled diabetes, and barrier disruption are the best-documented contributors.

The keyword is blunt, but the biology is not. Vaginal candidiasis is not a sexually transmitted infection in the conventional sense. Candida species are normal commensals in a substantial fraction of healthy women, and the infection reflects a loss of ecological control rather than a new acquisition. Understanding why that control fails is more useful than memorizing a list of "causes."

The colonization-to-overgrowth mechanism

Candida albicans exists in two forms. The yeast form is a single oval cell that colonizes the vagina without causing symptoms. The hyphal form is a filamentous, invasive shape that adheres to vaginal epithelium, secretes proteases, and provokes the itching and discharge of a symptomatic episode. The transition between these forms is the central event in candidiasis, and it is governed by local conditions rather than by the presence of the organism alone.

Vaginal epithelial cells store glycogen under the influence of estrogen. Lactobacillus species, dominated by L. crispatus and L. iners, ferment that glycogen to lactic acid. This keeps vaginal pH in the 3.8 to 4.5 range in reproductive-age women. Candida tolerates acid, but its adhesion and germination are constrained by a healthy Lactobacillus biofilm and by the low pH that community maintains. When Lactobacillus abundance falls, pH rises, glycogen remains available, and Candida gains a foothold.

The immune system adds another layer. Vaginal epithelial cells and neutrophils recognize Candida cell-wall components through pattern-recognition receptors and produce antimicrobial peptides and cytokines. Symptomatic infection typically reflects a mismatch: enough Candida to trigger inflammation, and an immune response vigorous enough to cause itching and irritation but not efficient enough to clear the organism. This is why some colonized women have no symptoms at all while others have recurrent episodes with minimal provocation.

The plain-language version: yeast is normally present, and the vagina keeps it in yeast form through acid, bacteria, and local immunity. A yeast infection is what happens when those brakes fail.

How common it is, and what the numbers show

Vaginal candidiasis is the second most common cause of vaginitis after bacterial vaginosis. Roughly 75 percent of women experience at least one episode in their lifetime, and about half of those who have one episode will have a second. Recurrent vulvovaginal candidiasis is defined by four or more symptomatic episodes in twelve months, and it affects a smaller but clinically distinct group, often estimated in the low single-digit percentage of women.

Candida albicans causes the large majority of episodes, commonly cited at 85 to 90 percent. The remainder involves C. glabrata, C. tropicalis, C. krusei, and other species. This matters because non-albicans species respond less reliably to standard azole therapy, which is one reason a "treatment-resistant" infection deserves culture rather than repeated empiric courses.

The estrogen dependence is visible across the lifespan. Before puberty and after menopause, vaginal candidiasis is uncommon because estrogen-driven glycogen deposition is low. Pregnancy, by contrast, raises estrogen substantially and is associated with higher colonization rates and more frequent symptomatic episodes, particularly in the second and third trimesters. Oral contraceptive use with higher estrogen content has been linked to increased risk in some studies, though the relationship is not uniform across formulations and the evidence is mixed.

Antibiotic exposure is the most consistently quantified trigger. Broad-spectrum antibiotics disrupt Lactobacillus populations, and the resulting rise in pH and loss of competitive inhibition predictably increases Candida colonization. The timing is not random: symptoms typically emerge during or shortly after the antibiotic course, which is why the association is easy to recognize in retrospect.

Edge cases that change the picture

Uncontrolled diabetes is a well-established risk factor, and the mechanism is specific. Hyperglycemia increases glucose availability in vaginal secretions, which favors Candida growth, and it impairs neutrophil function. Women with poorly controlled type 1 or type 2 diabetes have higher rates of colonization and symptomatic episodes, and recurrent candidiasis can be the presenting sign of undiagnosed diabetes.

Immunosuppression, whether from HIV, corticosteroids, or transplant-related therapy, increases both frequency and severity. The same applies to women receiving systemic chemotherapy. In these groups, non-albicans species and atypical presentations are more common, and response to standard topical therapy may be incomplete.

Estrogen-containing contraceptives, hormone replacement therapy, and pregnancy all shift the local environment toward glycogen availability and higher colonization. The counterintuitive detail here: douching and aggressive "feminine hygiene" products, which many women use to prevent infection, disrupt Lactobacillus and raise pH. The behavior intended to reduce risk can increase it. The same applies to scented washes, vaginal deodorants, and prolonged use of tight, non-breathable clothing that traps moisture.

Sexual activity is a nuanced edge case. Candida is not classified as a sexually transmitted infection, and treating male partners does not reduce recurrence in most cases. However, friction from intercourse can cause microtrauma to vaginal epithelium, and saliva and semen transiently raise pH, so some women notice episodes after increased sexual frequency. This is a trigger-modulated association, not evidence of transmission.

Misconceptions worth correcting

Several beliefs about yeast infections are common and wrong. The first is that yeast infections are sexually transmitted. They are not, in the standard sense, and partner treatment is not recommended for uncomplicated cases. The second is that discharge alone confirms the diagnosis. The classic presentation is white, thick, cottage-cheese-like discharge with vulvar itching and irritation, but discharge varies, and many other conditions mimic it.

The third misconception is that over-the-counter antifungals are appropriate for every episode. OTC products are labeled for uncomplicated cases in otherwise healthy women, and using them repeatedly without a confirmed diagnosis can delay treatment of bacterial vaginosis, trichomoniasis, or a non-albicans Candida species. The fourth is that yogurt or probiotics reliably prevent recurrence. Evidence for oral or vaginal probiotic prophylaxis is inconsistent, and the effect sizes in trials are modest at best.

The fifth misconception concerns diagnostic certainty. Symptoms overlap substantially with bacterial vaginosis and trichomoniasis, and self-diagnosis is unreliable. A woman who has had a prior confirmed episode and now has identical symptoms may reasonably use an OTC product, but new or atypical symptoms warrant clinical evaluation.

Comparison of treatment approaches

Approach Typical use Key limitation
Topical azole (OTC) Uncomplicated episodes, 1 to 7 days depending on formulation Not suited to non-albicans species or severe disease
Oral azole (prescription) Uncomplicated or recurrent episodes, clinician-directed Drug interactions; not for pregnancy without clinician guidance
Boric acid suppositories Often used for non-albicans or azole-resistant cases Not for pregnancy; requires clinician oversight
Probiotic adjuncts Adjunct only, evidence inconsistent Not a standalone treatment
Partner treatment Not standard No demonstrated benefit for recurrence
Culture-directed therapy Recurrent or refractory cases Requires access to testing

The pattern is clear: first-line therapy is azole-based, and the main decision points are severity, pregnancy status, and whether the species is albicans or not. None of these are self-diagnosable with confidence.

Practical actions and thresholds

The most useful practical step is to distinguish a first episode from a recurrent pattern. A single uncomplicated episode in a healthy non-pregnant woman can reasonably be treated with an OTC topical azole per labeling. Symptoms that do not improve within the expected course, or that recur within two months, warrant evaluation.

For recurrent episodes, the threshold is four or more symptomatic episodes in twelve months. At that point, culture confirmation and a clinician-directed maintenance strategy are appropriate. The same applies to any episode with atypical features: colored or malodorous discharge, ulceration, pelvic pain, fever, or symptoms that began after a new sexual partner.

Red-flag warnings as bullets:

Fever, pelvic pain, or systemic symptoms suggest complicated infection and require prompt evaluation. Symptoms in pregnancy should be managed with clinician guidance, because OTC self-treatment and some agents are not appropriate. Diabetes-related recurrence should prompt glucose review, not just repeated antifungal courses. Discharge with a fishy odor points toward bacterial vaginosis, which needs a different treatment. Recurrent non-albicans infection may not respond to standard azoles and needs culture-directed care. Any new or changing vaginal symptom after menopause deserves evaluation rather than assumption.

Practical steps that follow from the mechanism: avoid douching and scented products, wear breathable underwear, change out of wet clothing promptly, and complete prescribed antifungal courses even after symptoms resolve. These measures target the ecological conditions rather than the organism.

Limitations of what is known

The causal picture is strongest for antibiotics, uncontrolled diabetes, pregnancy, and immunosuppression. For other commonly cited triggers, including tight clothing, dietary sugar, and stress, the evidence is observational and inconsistent, and claims of strong causation overstate what studies show. Probiotic prevention remains an area of active but inconclusive research.

The deeper limitation is diagnostic. Symptom-based self-diagnosis misclassifies a meaningful share of episodes, and the distinction between colonization and infection is not always clear even with testing. A woman with recurrent symptoms and negative cultures may have a different condition entirely. The honest conclusion is that the mechanism is well understood at the ecological level, while individual triggers are more predictable for some women than others.